The United States Food and Drug Administration (F.D.A.) officials identified approximately 100 cases among the nearly 13 million vaccine recipients in the U.S. of a rare Nerve condition known as Guillain-Barré syndrome.

Regulators have determined that the chances of developing the condition are minimal, they occur three to five times higher among Johnson & Johnson vaccine recipients than among the general population in the United States. Officials strongly emphasize that the vaccine’s benefits still outweighed the risk of catching the neurological disease.

Guillain-Barre syndrome is described on the Mayo Clinic’s website as a rare disorder in which your body’s immune system attacks your nerves. Weakness and tingling in your extremities are usually the first symptoms. Sensations can quickly spread, eventually paralyzing your whole body. In its most severe form, Guillain-Barre syndrome is a medical emergency. Most people with the condition must be hospitalized to receive treatment.

In April, the F.D.A. warned about an increased risk of blood clots associated with low platelets concerning the Johnson & Johnson vaccine.